Grail Preparing for FDA Advisory Committee Meeting as Q2 Revenue Increases 26 Percent

Grail, a cancer early detection company, reported a 26 percent year-over-year revenue increase in Q2 and is preparing for an FDA advisory committee meeting expected in the fall regarding its product.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.